Discovery of selective small molecular TACE inhibitors for the treatment of rheumatoid arthritis

Current Medicinal Chemistry

Volumn 19, Issue 18, 2012, Pages 2924-2956

  Li, N G ^a   Shi, Z H ^b   Tang, Y P ^a   Wei Li, ^a   Lian Yin, ^a   Duan, J A ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Design; Inflammatory disease; Matrix metalloproteinases; Pharmacokinetic; Rheumatoid arthritis; Selective inhibitors; Structure activity relationship; Synthesis; Tumour necrosis factor converting enzyme; Zinc binding group

Indexed keywords

ADALIMUMAB; ANALGESIC AGENT; ANTHRANILIC ACID; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; HYDROXAMIC ACID; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR;

ARTICLE; DRUG DESIGN; HUMAN; INHIBITION KINETICS; MEDICAL RESEARCH; NONHUMAN; PATHOPHYSIOLOGY; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION;

EID: 84861881610     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800672120     Document Type: Article

References (138)

1. Lee, D.M.; Weinblatt, M.E. Rheumatoid arthritis. Lancet, 2001, 358(9285), 903-911.
2. O'Dell, J.R. Therapeutic strategies for rheumatoid arthritis. N. Engl. J. Med., 2004, 350(25), 2591-2602.
3. Firestein, G.S. Evolving concepts of rheumatoid arthritis. Nature, 2003, 423(6937), 356-361.
4. Olsen, N.J.; Stein, C.M. New drugs for rheumatoid arthritis. N. Engl. J. Med., 2004, 350(21), 2167-2179.
5. Choy, E.H.S.; Panayi, G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med., 2001, 344(12), 907-916.
6. Mcinnes, I.B.; Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol., 2007, 7(6), 429-442.
7. Pettit, A.R.; Walsh, N.C.; Manning, C.; Goldring, S.R.; Gravallese, E.M. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology, 2006, 45(9), 1068-1076.
8. Sano, H.; Engleka, K.; Mathern, P.; Hla, T.; Crofford, L.J.; Remmers, E.F.; Jelsema, C.L.; Goldmuntz, E.; Maciag, T.; Wilder, R.L. Coexpression of phosphotyrosine-containing proteins, platelet-derived growth factor-B, and fibroblast growth factor-1 in situ in synovial tissues of patients with rheumatoid arthritis and Lewis rats with adjuvant or streptococcal cell wall arthritis. J. Clin. Invest., 1993, 91(2), 553-565.
9. Yamanishi, Y.; Firestein, G.S. Pathogenesis of rheumatoid arthritis: The role of synoviocytes. Rheum. Dis. Clin. North. Am., 2001, 27(2), 355-371.
10. Kong, Y.Y.; Yoshida, H.; Sarosi, I.; Tan, H.-L.; Timms, E.; Capparelli, C.; Morony, S.; Oliveira-dos-Santos, A. J.; Van, G.; Itie, A.; Khoo, W.; Wakeham, A.; Dunstan, C.R.; Lacey, D.L.; Mak, T.W.; Boyle, W.J.; Penninger, J.M. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 1999, 397(6717), 315-323.
11. Rewatkar, P.V.; Kokil, G.R.; Verma, A.; Thareja, S. Rheumatoid arthritis: A new challenge in coming era. Mini. Rev. Med. Chem., 2010, 10(2), 98-107
12. Meagher, E.A. Cardiovascular and renovascular implications of COX-2 inhibition. Curr. Pharm. Des., 2004, 10(6), 603-611.
13. Bresalier, R.S.; Sandler, R.S.; Quan, H.; Bolognese, J.A.; Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton, D.; Lanas, A.; Konstam, M.A.; Baron, J.A.; Adenomatous polyp prevention on vioxx (APPROVe) trial investigators. cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med., 2005, 352(11), 1092-1102.
14. Solomon, S.D.; McMurray, J.J.; Pfeffer, M.A.; Wittes, J.; Fowler, R.; Finn, P.; Anderson, W.F.; Zauber, A.; Hawk, E.; Bertagnolli, M.; Adenoma prevention with celecoxib (APC) study investigators. cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med., 2005, 352(11), 1071-1080.
15. Bansback, N.J.; Regier, D.A.; Ara, R.; Brennan, A.; Shojania, K.; Esdaile, J.M.; Anis, A.H.; Marra, C.A. An overview of economic evaluations for drugs used in rheumatoid arthritis: Focus on tumour necrosis factor-alpha antagonists. Drugs, 2005, 65(4), 473-496.
16. Klinkhoff, A. Biological agents for rheumatoid arthritis: Targeting both physical function and structural damage. Drugs, 2004, 64(12), 1267-1283.
17. Aslanidis, S.; Pyrpasopoulou, A.; Douma, S.; Triantafyllou, A. Tumor necrosis factor-α antagonist-induced psoriasis: Yet another paradox in medicine, Clin. Rheumatol., 2008, 27(3), 377-380.
18. Engelmann, H.; Aderka, D.; Rubinstein, M.; Rotman, D.; Wallach, D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protecs cells from tumor necrosis factor toxicity. J. Biol. Chem., 1989, 264(20), 11974-11980.
19. Smith, C.A.; Davis, T.; Anderson, D.; Solam, L.; Beckmann, M.P.; Jerzy, R.; Dower, S.K.; Cosman, D; Goodwin, R.G. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science, 1990, 248(4958), 1019-1023.
20. Jones, E.Y.; Stuart, D.I.; Walker, N.P.C. Structure of tumor necrosis factor. Nature, 1989, 338(6212), 225-228.
21. Garnett, W.R.; Yunker, N. Treatment of Crohn's disease with infliximab. Am. J. Health Syst. Pharm., 2001, 58(4), 307-316.
22. van de Putte, L.B.A.; Atkins, C.; Malaise, M.; Sany, J.; Russell, A.; van Riel, P.L.C.M.; Settas, L.; Bijlsma, J.; Todesco, S.; Dougados, M.; Nash, P.; Emery, P.; Walter, N.; Kaul, M.; Fischkoff, S.; Kupper, H. Efficacy and safety of adalimumab as monotherapy in patients with rgeumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis., 2004, 63(5), 508-516.
23. Keystone, E.C.; Genovese, M.C.; Klareskog, L.; Hsia, E.C.; Hall, S.T.; Miranda, P.C.; Pazdur, J.; Bae, S.C.; Palmer, W.; Zrubek, J.; Wiekowski, M.; Visvanathan, S.; Wu, Z.; Rahman, M.U.; GOFORWARD Study. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GOFORWARD study. Ann. Rheum. Dis., 2009, 68(6), 789-796.
24. Keystone, E.; van der Heijde, D.; Jr. Mason, D.; Landewe, R.; van Vollenhoven, R.; Combe, B.; Emery, P.; Strand, V.; Mease, P.; Desai, C.; Pavelka, K. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis. Arthritis Rheum., 2008, 58(11), 3319-3329.
25. Sandborn, W.J.; Feagan, B.G.; Stoinov, S.; Honiball, P.J.; Rutgeerts, P.; Mason, D.; Bloomfield, R.; Schreiber, S.; PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's Disease. N. Engl. J. Med., 2007, 357(3), 228-238.
26. Benucci, M.; Gobbi, F.L.; Fossi, F.; Manfredi, M.; Del Rosso, A. Druginduced Lupus after treatment with infliximab in rheumatoid arthritis. Jcr-J. Clin. Rheumatol., 2005, 11(1), 47-49.
27. Mohler, K.M.; Sleath, P.R.; Fitzner, J.N.; Cerretti, D.P.; Alderson, M.; Kerwar, S.S.; Dauphine S.T.; Otten-Evans, C.; Greenstreet, T.; Weerawarna, K.; Kronheim, S.R.; Petersen, M.; Gerhart, M.; Kozlosky, C.J.; March, C.J.; Black, R.A. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature, 1994, 370(6486), 218-220.
28. Gearing, A.J.H.; Beckett, P.; Christodoulou, M.; Churchill, M.; Clements, J.; Davidson, A.H.; Drummond, A.H.; Galloway, W.A.; Gilbert, R.; Gordon, J.L.; Leber, T.M.; Mangan, M.; Miller, K.; Nayee, P.; Owen, K.; Patel, S.; Thomas, W.; Wells, G.; Wood, L.M.; Wolley, K. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature, 1994, 370(6490), 555-557.
29. McGeehan, G.M.; Becherer, J.D.; Bast, R.C., Jr.; Boyer, C.M.; Champion, B.; Connolly, K.M.; Conway, J.G.; Furdon, P.; Karp, S.; Kidao, S.; McElroy, A.B.; Nichols, J.; Pryzwansky, K.M.; Schoenen, F.; Sekut, L.; Truesdale, A.; Verghese, M.; Warner, J.; Ways, J.P. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature, 1994, 370(6490), 558-561.
30. Black, R.A.; Rauch, C.T.; Kozlosky, C.J.; Peschon, J.J.; Slack, J.L.; Wolfson, M.F.; Castner, B.J.; Stocking, K.L.; Reddy, P.; Srinivasan, S.; Nelson, N.; Boiani, N.; Schooley, K.A.; Gerhart, M.; Davis, R.; Fitzner, J.N.; Johnson, R.S.; Paxton, R.J.; March, C.J.; Cerretti, D.P. A metalloproteinase disintegrin that releases tumor-necrosis factor-α from cells. Nature, 1997, 385(6618), 729-733.
31. Moss, M.L.; Jin, S.-L.C.; Milla, M.E.; Burkhart, W.; Carter, H.L.; Chen, W.- J.; Clay, W.C.; Didsbury, J.R.; Hassler, D.; Hoffman, C.R.; Kost, T.A.; Lambert, M.H.; Leesnitzer, M.A.; McCauley, P.; McGeehan, G.; Mitchell, J.; Moyer, M.; Pahel, G.; Rocque, W.; Overton, L.K.; Schoenen, F.; Seaton, T.; Su, J.-L.; Warner, J.; Willard, D.; Becherer, J.D. Cloning of a disintegrin metalloproteinase that processes precursor tumor-necrosis factor-α. Nature, 1997, 385(6618), 733-736.
32. Black, R.A.; White, J.M. ADAMS: Focus on the protease domain. Curr. Opin. Cell Biol., 1998, 10(5), 654-659.
33. Moss, M.L.; White, J.M.; Lambert, M.H.; Andrews, R.C. TACE and other ADAM proteases as targets for drug discovery. Drug Discov. Today, 2001, 6(8), 417-426.
34. Schlondorff, J.; Becherer, J.D.; Blobel, C.P. Intracellular maturation and localization of the tumour necrosis factor α convertase (TACE). Biochem. J., 2000, 347(Pt 1), 131-138.
35. Li, N.-G.; Shi, Z.-H.; Tang, Y.-P.; Duan, J.-A. Selective matrix metalloproteinase inhibitors for cancer. Curr. Med. Chem., 2009, 16(29), 3805-3827.
36. Leung, D.; Abbenante, G.; Fairlie, D.P. Protease inhibitors: Current status and future prospects. J. Med. Chem., 2000, 43(3), 305-341.
37. Li, N.-G.; Shi, Z.-H.; Tang, Y.-P.; Wang, Z.-J.; Song, S.-L.; Qian, L.-H.; Qian, D.-W.; Duan, J.-A. New hope for the treatment of osteoarthritis through selective inhibition of MMP-13. Curr. Med. Chem., 2011, 18(7), 977-1001.
38. Fairlie, D.P.; Tyndall, J.D.A.; Reid, R.C.; Wong, A.K.; Abbenante, G.; Scanlon, M.J.; March, D.R.; Bergman, D.A.; Chai, C.L.L.; Burkett, B.A. Conformational selection of inhibitors and substrates by proteolytic enzymes: Implications for drug design and polypeptide processing. J. Med. Chem., 2000, 43(7), 1271-1281.
39. Tyndall, J.D.A.; Nall, T.; Fairlie, D.P. Proteases universally recognize beta strands in their active site. Chem. Rev., 2005, 105(3), 973-1000.
40. Tyndall, J.D.A.; Fairlie, D.P. Conformational homogeneity in molecular recognition by proteolytic enzymes. J. Mol. Recognit., 1999, 12(6), 363-370.
41. Loughlin, W.A.; Tyndall, J.D.A.; Glenn, M.P.; Fairlie, D.P. Beta-strand mimetics. Chem. Rev., 2004, 104(12), 6085-6117.
42. Schechter, I.; Berger, A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun., 1967, 27(2), 157-162.
43. Nemunaitis, J.; Poole, C.; Primrose, J.; Rosemurgy, A.; Malfetano, J.; Brown, P.; Berrington, A.; Cornish, A.; lynch, K.; Rasmussen, H.; Kerr, D.; Cox, D.; Millar, A. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of a biologically active and tolerable dose for longer-term studies. Clin. Cancer Res., 1998, 4(5), 1101-1109.
44. Wojtowicz-Praga, S.; Torri, J.; Johnson, M.; Steen, V.; Marshall, J.; Ness, E.; Dickson, R.; Sale, M.; Rasmussen, H.S.; Chiodo, T.A.; Hawkins, M.J. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Oncol., 1998, 16(6), 2150-2156.
45. Watanabe, Y.; Haruyama, T.; Akaike, T. Liver-derived matrix metalloproteinase-9 (gelatinase B) recruits progenitor cells from bone marrow into the blood circulation. Biol. Pharm. Bull., 2003, 26(4), 564-568.
46. Holmbeck, K.; Bianco, P.; Caterina, J.; Yamada, S.; Kromer, M.; Kuznetsov, S.A.; Mankani, M.; Robey, P.G.; Poole, A.R.; Pidoux, I.; Ward, J.M.; Hansen, H.B. MT1-MMP deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell, 1999, 99(1), 81-92.
47. Yan, Y.; Shirakabe, K.; Werb, Z. The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G proteincoupled receptors. J. Cell Biol., 2002, 158(2), 221-226.
48. Hattori, M.; Osterfield, M.; Flanagan, J.G. Regulated cleavage of a contactmediated axon repellent. Science, 2000, 289(5483), 1360-1365.
49. Lammich, S.; Kojro, E.; Postina, R.; Gilbert, S.; Pfeiffer, R.; Jasionowski, M.; Haass, C.; Fahrenholz, F. Constitutive and regulated α-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc. Natl. Acad. Sci. USA, 1999, 96(7), 3922-3927.
50. Hartmann, D.; de Strooper, B.; Serneels, L.; Craessaerts, K.; Herreman, A.; Annaert, W.; Umans, L.; Lubke, T.; Illert, A.L.; von Figura, K.; Saftig, P. The disintegrin/metalloprotease ADAM 10 is essential for Notch signaling but not for alpha-secretase activity in fibroblasts. Hum. Mol. Genet., 2002, 11(21), 2615-2624.
51. Maskos, K.; Fernandez-Catalan, C.; Humber, R.; Bourenkov, G.P.; Bartunik, H.; Eliestad, G.A.; Reddy, P.; Wolfson, M.F.; Rauch, C.T.; Castner, B.J.; Davis, R.; Clarke, H.R.G.; Petersen, M.; Fitzner, J.N.; Cerretti, D.P.; March, C.J.; Paxton, R.J.; Black, R.A.; Bode, W. Crystal structure of the catalytic domain of human tumor necrosis factor-α-converting enzyme. Proc. Natl. Acad. Sci. USA, 1998, 95(7), 3408-3412.
52. Beckett, R.P.; Davidson, A.H.; Drummond, A.H.; Huxley, P.; Whittaker, M. Recent advances in matrix metalloproteinase inhibitor research. Drug Discov. Today, 1996, 1(1), 16-26.
53. MacPherson, L.J.; Bayburt, E.K.; Capparelli, M.P.; Carroll, B.J.; Goldstein, R.; Justice, M.R.; Zhu, L.; Hu, S.-I.; Melton, R.A.; Fryer, L.; Goldberg, R.L.; Doughty, J.R.; Spirito, S.; Blancuzzi, V.; Wilson, D.; O'Byrne, E.M.; Ganu, V.; Parker, D.T. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J. Med. Chem., 1997, 40(16), 2525-2532.
54. Li, Y.-C.; Zhang, X.; Melton, R.; Ganu, V.; Gonnella, N.C. Solution structure of the catalytic domain of human stromelysin-1 complexed to a potent, nonpeptidic inhibitor. Biochemistry, 1998, 37(40), 14048-14056.
55. Nar, H.; Werle, K.; Bauer, M.M.; Dollinger, H.; Jung, B. Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor. J. Mol. Biol., 2001, 312(4), 743-751.
56. Xue, C.-B.; He, X.; Corbett, R.L.; Roderick, J.; Wasserman, Z.R.; Liu, R.-Q.; Jaffee, B.D.; Covington, M.B.; Qian, M.; Trzaskos, J.M.; Newton, R.C.; Magolda, R.L.; Wexler, R.R.; Decicco, C.P. Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-α converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-α release. J. Med. Chem., 2001, 44(21), 3351-3354.
57. Chen, J.M.; Jin, G.; Sung, A.; Levin, J.I. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1' groups. Bioorg. Med. Chem. Lett., 2002, 12(8), 1195-1198.
58. Levin, J.I.; Du, M.T.; DiJoseph, J.F.; Killar, L.M.; Sung, A.; Walter, T.; Sharr, M.A.; Roth, C.E.; Moy, F.J.; Powers, R.; Jin, G.; Cowling, R.; Skotnicki, J.S. The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position. Bioorg. Med. Chem. Lett., 2001, 11(2), 235-238.
59. Levin, J.I.; Chen, J.; Du, M.; Hogan, M.; Kincaid, S.; Nelson, F.C.; Venkatesan, A.M.; Wehr, T.; Zask, A.; DiJoseph, J.; Killar, L.M.; Skala, S.; Sung, A.; Sharr, M.; Roth, C.; Jin, G.; Cowling, R.; Mohler, K.M.; Black, R.A.; March, C.J.; Skotnicki, J.S. The discovery of anthranilic acid-Based MMP inhibitors. Part 2: SAR of the 5-position and P1' groups. Bioorg. Med. Chem. Lett., 2001, 11(16), 2189-2192.
60. Levin, J.I.; Chen, J.M.; Du, M.T.; Nelson, F.C.; Wehr, T.; DiJoseph, J.F.; Killar, L.M.; Skala, S.; Sung, A.; Sharr, M.A.; Roth, C.E.; Jin, G.; Cowling, R.; Di, L.; Sherman, M.; Xu, Z.B.; March, C.J.; Mohler, K.M.; Black, R.A.; Skotnicki, J.S. The discovery of anthranilic acid-based mmp inhibitors. Part 3: Incorporation of basic amines. Bioorg. Med. Chem. Lett., 2001, 11(22), 2975-2978.
61. Levin, J.I.; Chen, J.M.; Du, M.T.; Nelson, F.C.; Killar, L.M.; Skala, S.; Sung, A.; Jin, G.; Cowling, R.; Barone, D.; March, C.J.; Mohler, K.M.; Black, R.A.; Skotnicki, J.S. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group. Bioorg. Med. Chem. Lett., 2002, 12(8), 1199-1202.
62. Levin, J.I.; Chen, J.M.; Cheung, K.; Cole, D.; Crago, C.; Delos Santos, E.; Du, X.; Khafizova, G.; MacEwan, G.; Niu, C.; Salaski, E.J.; Zask, A.; Cummons, T.; Sung, A.; Xu, J.; Zhang, Y.; Xu, W.; Ayral-Kaloustian, S.; Jin, G.; Cowling, R.; Barone, D.; Mohler, K.M.; Black, R.A.; Skotnicki, J.S. Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates. Bioorg. Med. Chem. Lett., 2003, 13(16), 2799-2803.
63. Levin, J.I.; Chen, J.M.; Laakso, L.M.; Du, M.; Du, X.; Venkatesan, A.M.; Sandanayaka, V.; Zask, A.; Xu, J.; Xu, W.; Zhang, Y.; Skotnicki, J.S. Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates. Bioorg. Med. Chem. Lett., 2005, 15(19), 4345-4349.
64. Gwaltney II, S.L.; Imade, H.M.; Li, Q.; Gehrke, L.; Credo, R.B.; Warner, R.B.; Lee, J.Y.; Kovar, P.; Frost, D.; Ng, S.-C.; Sham, H.L. Novel sulfonate derivatives: Potent antimitotic agents. Bioorg. Med. Chem. Lett., 2001, 11(13), 1671-1673.
65. Soll, R.M.; Lu, T.; Tomczuk, B.; Illig, C.R.; Fedde, C.; Eisennagel, S.; Bone, R.; Murphy, L.; Spurlino, J.; Salemme, F.R. Amidinohydrazones as guanidine bioisosteres: Application to a new class of potent, selective and orally bioavailable, non-amide-based small-molecule thrombin inhibitors. Bioorg. Med. Chem. Lett., 2000, 10(1), 1-4.
66. Levin, J.I.; Du, M.T. Sulfonate ester hydroxamic acids as potent and selective inhibitors of TACE enzyme. Drug Des. Discov., 2003, 18(4), 123-126.
67. Tsukida, T.; Moriyama, H.; Inoue, Y.; Kondo, H.; Yoshinob, K.; Nishimura, S.-I. Synthesis and biological activity of selective azasugar-based TACE inhibitors. Bioorg. Med. Chem. Lett., 2004, 14(6), 1569-1572.
68. Venkatesan, A.M.; Davis, J.M.; Grosu, G.T.; Baker, J.; Zask, A.; Levin, J.I.; Ellingboe, J.; Skotnicki, J.S.; DiJoseph, J.F.; Sung, A.; Jin, G.; Xu, W.; McCarthy, D.J.; Barone, D. Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-α converting enzyme and matrix metalloproteinase inhibitors. J. Med. Chem., 2004, 47(25), 6255-6269.
69. Nelson, F.C.; Santos, E.D.; Levin, J.I.; Chen, J.M.; Skotnicki, J.S.; DiJoseph, J.F.; Sharr, M.A.; Sung, A.; Killar, L.M.; Cowling, R.; Jin, G.; Roth, C.E.; Albright, J.D. Benzodiazepine inhibitors of the MMPs and TACE. Bioorg. Med. Chem. Lett., 2002, 12(20), 2867-2870.
70. Levin, J.I.; Nelson, F.C.; Santos, E.D.; Du, M.T.; MacEwan, G.; Chen, J.M.; Ayral-Kaloustian, S.; Xu, J.; Jin, G.; Cummons, T.; Barone, D. Benzodiazepine inhibitors of the MMPs and TACE. Part 2. Bioorg. Med. Chem. Lett., 2004, 14(16), 4147-4151.
71. Zask, A.; Kaplan, J.; Du, X.; MacEwan, G.; Sandanayaka, V.; Eudy, N.; Levin, J.; Jin, G.; Xu, J.; Cummons, T.; Barone, D.; Ayral-Kaloustian, S.; Skotnicki, J. Synthesis and SAR of diazepine and thiazepine TACE and MMP inhibitors. Bioorg. Med. Chem. Lett., 2005, 15(6), 1641-1645.
72. Park, K.; Aplasca, A.; Du, M.T.; Sun, L.; Zhu, Y.; Zhang, Y.; Levin, J.I. Design and synthesis of butynyloxyphenyl β-sulfone piperidine hydroxamates as TACE inhibitors. Bioorg. Med. Chem. Lett., 2006, 16(15), 3927-3931.
73. Condon, J.S.; Joseph-McCarthy, D.; Levin, J.I.; Lombart, H.-G.; Lovering, F.E.; Sun, L.; Wang, W.; Xua, W.; Zhang, Y. Identification of potent and selective TACE inhibitors via the S1 pocket. Bioorg. Med. Chem. Lett., 2007, 17(1), 34-39.
74. Lombart, H.-G.; Feyfant, E.; Joseph-McCarthy, D.; Huang, A.; Lovering, F.; Sun, L.; Zhu, Y.; Zeng, C.; Zhang, Y.; Levin, J. Design and synthesis of 3,3- piperidine hydroxamate analogs as selective TACE inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(15), 4333-4337.
75. Levin, J.I.; Venkatesan, A.M.; Chen, J.M.; Zask, A.; Sandanayaka, V.P.; Du, M.T.; Baker, J.L. Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors. U.S. Patent 6,358,980, March 19, 2002.
76. Huang, A.; Joseph-McCarthy, D.; Lovering, F.; Sun, L.; Wang, W.; Xu, W.; Zhu, Y.; Cui, J.; Zhang, Y.; Levin, J.I. Structure-based design of TACE selective inhibitors: Manipulations in the S1?-S3' pocket. Bioorg. Med. Chem., 2007, 15(18), 6170-6181.
77. Xue, C.-B.; Voss, M.E.; Nelson, D.J.; Duan, J.J.-W.; Cherney, R.J.; Jacobson, I.C.; He, X.; Roderick, J.; Chen, L.; Corbett, R.L.; Wang, L.; Meyer, D.T.; Kennedy, K.; DeGrado, W. F.; Hardman, K.D.; Teleha, C.A.; Jaffee, B.D.; Liu, R.-Q.; Copeland, R.A.; Covington, M.B.; Christ, D.D.; Trzaskos, J.M.; Newton, R.C.; Magolda, R.L.; Wexler, R.R.; Decicco, C.P. Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor α release in vitro and in vivo. J. Med. Chem., 2001, 44(16), 2636-2660.
78. Duan, J.J.-W.; Chen, L.; Wasserman, Z.R.; Lu, Z.; Liu, R.-Q.; Covington, M.B.; Qian, M.; Hardman, K.D.; Magolda, R.L.; Newton, R.C.; Christ, D.D.; Wexler, R.R.; Decicco, C.P. Discovery of γ-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor α converting enzyme: Design, synthesis, and structure-activity relationships. J. Med. Chem., 2002, 45(23), 4954-4957.
79. Duan, J.J.-W.; Lu, Z.; Xue, C.-B.; He, X.; Seng, J.L.; Roderick, J.J.; Wasserman, Z.R.; Liu, R.-Q.; Covington, M.B.; Magolda, R.L.; Newton, R.C.; Trzaskos, J.M.; Decicco, C.P. Discovery of N-hydroxy-2-(2-oxo-3- pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-α converting enzyme (TACE). Bioorg. Med. Chem. Lett., 2003, 13(12), 2035-2040.
80. Xue, C.-B.; He, X.; Roderick, J.; Corbett, R.L.; Duan, J.J.-W.; Liu, R.-Q.; Covington, M.B.; Newton, R.C.; Trzaskos, J.M.; Magolda, R.L.; Wexler, R.R.; Decicco, C.P. Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 1: Lead identification. Bioorg. Med. Chem. Lett., 2003, 13(24), 4293-4297.
81. Xue, C.-B.; He, X.; Roderick, J.; Corbett, R.L.; Duan, J.J.-W.; Liu, R.-Q.; Covington, M.B.; Qian, M.; Ribadeneira, M.D.; Vaddi, K.; Christ, D.D.; Newton, R.C.; Trzaskos, J.M.; Magolda, R.L.; Wexler, R.R.; Decicco, C.P. Rational Design, Synthesis and structure-activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 2: Lead optimization. Bioorg. Med. Chem. Lett., 2003, 13(24), 4299-4304.
82. Xue, C.-B.; Chen, X.-T.; He, X.; Roderick, J.; Corbett, R.L.; Ghavimi, B.; Liu, R.-Q.; Covington, M.B.; Qian, M.; Ribadeneira, M.D.; Vaddi, K.; Trzaskos, J.M.; Newton, R.C.; Duan, J.J.-W.; Decicco, C.P. Synthesis and structure-activity relationship of a novel sulfone series of TNF-α converting enzyme inhibitors. Bioorg. Med. Chem. Lett., 2004, 14(17), 4453-4459.
83. DasGupta, S.; Murumkar, P.R.; Giridhar, R.; Yadav, M.R. Studies on novel 2-imidazolidinones and tetrahydropyrimidin-2(1H)-ones as potential TACE inhibitors: Design, synthesis, molecular modeling, and preliminary biological evaluation. Bioorg. Med. Chem., 2009, 17(10), 3604-3617.
84. Cherney, R.J.; Mo, R.; Meyer, D.T.; Hardman, K.D.; Liu, R.-Q.; Covington, M.B.; Qian, M.; Wasserman, Z.R.; Christ, D.D.; Trzaskos, J.M.; Newton, R.C.; Decicco, C.P. Sultam hydroxamates as novel matrix metalloproteinase inhibitors. J. Med. Chem., 2004, 47(12), 2981-2983.
85. Cherney, R.J.; King, B.W.; Gilmore, J.L.; Liu, R.-Q.; Covington, M.B.; Duan, J.J.-W.; Decicco, C.P. Conversion of potent MMP inhibitors into selective TACE inhibitors. Bioorg. Med. Chem. Lett., 2006, 16(4), 1028-1031.
86. Skotnicki, J.S.; Levin, J.I. Chapter 16. TNF-α converting enzyme (TACE) as a therapeutic target. Annu. Rep. Med. Chem., 2003, 38, 153-162.
87. Gilmore, J.L.; King, B.W.; Harris, C.; Maduskuie, T.; Mercer, S.E.; Liu, R.- Q.; Covington, M.B.; Qian, M.; Ribadeneria, M.D.; Vaddi, K.; Trzaskos, J.M.; Newton, R.C.; Decicco, C.P.; Duan, J.J.-W. Synthesis and structure- activity relationship of a novel, achiral series of TNF-α converting enzyme inhibitors. Bioorg. Med. Chem. Lett., 2006, 16(10), 2699-2704.
88. Chen, X.-T.; Ghavimi, B.; Corbett, R.L.; Xue, C.-B.; Liu, R.-Q.; Covington, M.B.; Qian, M.; Vaddi, K.G.; Christ, D.D.; Hartman, K.D.; Ribadeneira, M.D.; Trzaskos, J.M.; Newton, R.C.; Decicco, C.P.; Duan, J.J.-W. A new 4- (2-methylquinolin-4-ylmethyl)phenyl P1' group for the β-amino hydroxamic acid derived TACE inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(7), 1865-1870.
89. Ott, G.R.; Asakawa, N.; Lu, Z.; Liu, R.-Q.; Covington, M.B.; Vaddi, K.; Qian, M.; Newton, R.C.; Christ, D.D.; Traskos, J.M.; Decicco, C.P.; Duan, J.J.-W. α,β-Cyclic-β-benzamido hydroxamic acids: Novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-α converting enzyme (TACE). Bioorg. Med. Chem. Lett., 2008, 18(2), 694-699.
90. Wasserman, Z.R.; Duan, J.J.-W.; Voss, M.E.; Xue, C.-B.; Cherney, R.J.; Nelson, D.J.; Hardman, K.D.; Decicco, C.P. Identification of a selectivity determinant for inhibition of tumor necrosis factor-α converting enzyme by comparative modeling. Chem. Biol., 2003, 10(3), 215-223.
91. Duan, J.J.-W.; Chen, L.; Lu, Z.; Xue, C.-B.; Liu, R.-Q.; Covington, M.B.; Qian, M.; Wasserman, Z.R.; Vaddi, K.; Christ, D.D.; Trzaskos, J.M.; Newton, R.C.; Decicco, C.P. Discovery of β-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(1), 241-246.
92. Ott, G.R.; Asakawa, N.; Liu, R.-Q.; Covington, M.B.; Qian, M.; Vaddi, K.; Newton, R.C.; Trzaskos, J.M.; Christ, D.D.; Galya, L.; Scholz, T.; Marshall, W.; Duan, J.J.-W. α,β-Cyclic-β-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-α converting enzyme (TACE). Bioorg. Med. Chem. Lett., 2008, 18(4), 1288-1292.
93. Liu, R.; Magolda, R.; Newton, R.; Duan, J.; Vaddi, K.; Madskuie, T.; Qian, M.; Collins, R.; Taylor, T.; Giannaris, J. Pharmacological profile of DPC 333, a selective TACE inhibitor. Inflamm. Res., 2002, 51, A27.
94. Zhu, Z.; Mazzola, R.; Sinning, L.; McKittrick, B.; Niu, X.; Lundell, D.; Sun, J.; Orth, P.; Guo, Z.; Madison, V.; Ingram, R.; Beyer, B.M. Discovery of novel hydroxamates as highly potent tumor necrosis factor-α converting enzyme inhibitors: Part I-Discovery of two binding modes. J. Med. Chem., 2008, 51(4), 725-736.
95. Mazzola Jr., R.D.; Zhu, Z.; Sinning, L.; McKittrick, B.; Lavey, B.; Spitler, J.; Kozlowski, J.; Shih, N.-Y.; Zhou, G.; Guo, Z.; Orth, P.; Madison, V.; Sun, J.; Lundell, D.; Niu, X. Discovery of novel hydroxamates as highly potent tumor necrosis factor-α converting enzyme inhibitors. Part II: Optimization of the S3, pocket. Bioorg. Med. Chem. Lett., 2008, 18(21), 5809-5814.
96. Guo, Z.; Orth, P.; Wong, S.-C.; Lavey, B.J.; Shih, N.-Y.; Niu, X.; Lundell, D.J.; Madison, V.; Kozlowski, J.A. Discovery of novel spirocyclopropyl hydroxamate and carboxylate compounds as TACE inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(1), 54-57.
97. Zhang, C.; Lovering, F.; Behnke, M.; Zask, A.; Sandanayaka, V.; Sun, L.; Zhu, Y.; Xu, W.; Zhang, Y.; Levin, J.I. Synthesis and activity of quinolinylmethyl P1' α-sulfone piperidine hydroxamate inhibitors of TACE. Bioorg. Med. Chem. Lett., 2009, 19(13), 3445-3448.
98. Barlaam, B.; Bird, T.G.; Lambert-van der Brempt, C.; Campbell, D.; Foster, S. J.; Maciewicz, R. New α-Substituted Succinate-Based Hydroxamic Acids as TNFα Convertase Inhibitors. J. Med. Chem., 1999, 42(23), 4890-4908.
99. White, A.D.; Bocan, T.M.A.; Boxer, P.A.; Peterson, J.T.; Schrier, D. Emerging Therapeutic Advances for the Development of Second Generation Matrix Metalloproteinase Inhibitors. Curr. Pharm. Des., 1997, 3(1), 45-58.
100. Holms, J.; Mast, K.; Marcotte, P.; Elmore, I.; Li, J.; Pease, L.; Glaser, K.; Morgan, D.; Michaelides, M.; Davidsen, S. Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-α converting enzyme. Bioorg. Med. Chem. Lett., 2001, 11(22), 2907-2910.
101. Letavic, M.A.; Axt, M.Z.; Barberia, J.T.; Carty, T.J.; Danley, D.E.; Geoghegan, K.F.; Halim, N.S.; Hoth, L.R.; Kamath, A.V.; Laird, E.R.; Lopresti-Morrow, L.L.; McClure, K.F.; Mitchell, P.G.; Natarajan, V.; Noe, M.C.; Pandit, J.; Reeves, L.; Schulte, G.K.; Snow, S.L.; Sweeney, F.J.; Tan, D.H.; Yu, C.H. Synthesis and biological activity of selective pipecolic acidbased TNF-α converting enzyme (TACE) inhibitors. Bioorg. Med. Chem. Lett., 2002, 12(10), 1387-1390.
102. Lovejoy, B.; Welch, A.R.; Carr, S.; Luong, C.; Broka, C.; Hendricks, R.T.; Campbell, J.A.; Walker, K.A.M.; Martin, R.; Van Wart, H.; Browner, M.F. Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors. Nat. Struct. Biol., 1999, 6(3), 217-221.
103. Sawa, M.; Kiyoi, T.; Kurokawa, K.; Kumihara, H.; Yamamoto, M.; Miyasaka, T.; Ito, Y.; Hirayama, R.; Inoue, T.; Kirii, Y.; Nishiwaki, E.; Ohmoto, H.; Maeda, Y.; Ishibushi, E.; Inoue, Y.; Yoshino, K.; Kondo, H. New type of metalloproteinase inhibitor: Design and synthesis of new phosphonamide-based hydroxamic acids. J. Med. Chem., 2002, 45(4), 919-929.
104. Sawa, M.; Tsukamoto, T.; Kiyoi, T.; Kurokawa, K.; Nakajima, F.; Nakada, Y.; Yokota, K.; Inoue, Y.; Kondo, H.; Yoshino, K. New strategy for antedrug application: Development of metalloproteinase inhibitors as antipsoriatic drugs. J. Med. Chem., 2002, 45(4), 930-936.
105. Sawa, M.; Kurokawa, K.; Inoue, Y.; Kondo, H.; Yoshino, K. Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-α converting enzyme (TACE). Bioorg. Med. Chem. Lett., 2003, 13(12), 2021-2024.
106. Cherney, R.J.; Duan, J.J.-W.; Voss, M.E.; Chen, L.; Wang, L.; Meyer, D.T.; Wasserman, Z.R.; Hardman, K.D.; Liu, R.-Q.; Covington, M.B.; Qian, M.; Mandlekar, S.; Christ, D.D.; Trzaskos, J.M.; Newton, R.C.; Magolda, R.L.; Wexler, R.R.; Decicco, C.P. Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-α converting enzyme inhibitors. J. Med. Chem., 2003, 46(10), 1811-1823.
107. Chen, J.J.; Dewdney, N.; Lin, X.; Martin, R.L.; Walker, K.A.M.; Huang, J.; Chu, F.; Eugui, E.; Mirkovich, A.; Kim, Y.; Sarma, K.; Arzeno, H.; Van Wart, H.E. Design and synthesis of orally active inhibitors of TNF synthesis as anti-rheumatoid arthritis drugs. Bioorg. Med. Chem. Lett., 2003, 13(22), 3951-3954.
108. Ott, G.R.; Asakawa, N.; Lu, Z.; Anand, R.; Liu, R.-Q.; Covington, M.B.; Vaddi, K.; Qian, M.; Newton, R.C.; Christ, D.D.; Trzaskos, J.M.; Duan, J.J.- W. Potent, exceptionally selective, orally bioavailable inhibitors of TNF-α converting enzyme (TACE): Novel 2-substituted-1H-benzo[d]imidazol-1- yl)methyl)benzamide P1' substituents. Bioorg. Med. Chem. Lett., 2008, 18(5), 1577-1582.
109. Lu, Z.; Ott, G.R.; Anand, R.; Liu, R.-Q.; Covington, M.B.; Vaddi, K.; Qian, M.; Newton, R.C.; Christ, D.D.; Trzaskos, J.; Duan, J.J.-W. Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-α converting enzyme (TACE): Discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1' substituents. Bioorg. Med. Chem. Lett., 2008, 18(6), 1958-1962.
110. Park, K.; Gopalsamy, A.; Aplasca, A.; Ellingboe, J.W.; Xu, W.; Zhang, Y.; Levin, J.I. Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-α converting enzyme (TACE) inhibitors. Bioorg. Med. Chem., 2009, 17(11), 3857-3865.
111. Kamei, N.; Tanaka, T.; Kawai, K.; Miyawaki, K.; Okuyama, A.; Murakami, Y.; Arakawa, Y.; Haino, M.; Harada, T.; Shimano, M. Reverse hydroxamatebased selective TACE inhibitors. Bioorg. Med. Chem. Lett., 2004, 14(11), 2897-2900.
112. Levin, J. The design and synthesis of aryl hydroxamic acid inhibitors of MMPs and TACE. Curr. Top. Med. Chem. 2004, 4(12), 1289-1310.
113. Rao, B.G. Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies. Curr. Pharm. Des. 2005, 11(3), 295-322.
114. Freskos, J.N.; Mischke, B.V.; DeCrescenzo, G.A.; Heintz, R.; Getman, D.P.; Howard, S.C.; Kishore, N.N.; McDonald, J.J.; Munie, G.E.; Rangwala, S.; Swearingen, C.A.; Voliva, C.; Welsch, D.J. Discovery of a novel series of selective MMP inhibitors: Identification of the γ-sulfone-thiols. Bioorg. Med. Chem. Lett., 1999, 9(7), 943-948.
115. Govinda Rao, B.; Bandarage, U.K.; Wang, T.; Come, J.H.; Perola, E.; Wei, Y.; Tian, S.-K.; Saunders, J.O. Novel thiol-based TACE inhibitors: Rational design, synthesis, and SAR of thiol-containing aryl sulfonamides. Bioorg. Med. Chem. Lett., 2007, 17(8), 2250-2253.
116. Fisher, J.F.; Mobashery, S. Recent advances in mmp inhibitor design. Cancer Metastasis Rev., 2006, 25(1), 115-136.
117. Duan, J.J.-W.; Lu, Z.; Wasserman, Z.R.; Liu, R.-Q.; Covington, M.B.; Decicco, C.P. Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-a converting enzyme. Bioorg. Med. Chem. Lett., 2005, 15(12), 2970-2973.
118. Moy, F.J.; Chanda, P.K.; Chen, J.; Cosmi, S.; Edris, W.; Levin, J.I.; Rush, T.S.; Wilhelm, J.; Powers, R. Impact of mobility on structure-based drug design for the MMPs. J. Am. Chem. Soc., 2002, 124(43), 12658-12659.
119. Bandarage, U.K.; Wang, T.; Come, J.H.; Perola, E.; Wei, Y.; Govinda Rao, B. Novel thiol-based TACE inhibitors. Part 2: Rational design, synthesis, and SAR of thiol-containing aryl sulfones. Bioorg. Med. Chem. Lett., 2008, 18(1), 44-48.
120. Gilmore, J.L.; King, B.W.; Asakawa, N.; Harrison, K.; Tebben, A.;
121. Park, S.-K.; Han, S.B.; Lee, K.; Lee, H.J.; Kho, Y.H.; Chun, H.; Choi, Y.; Yang, J.Y.; Yoon, Y.D.; Lee, C.-W.; Kim, H.M.; Choi, H.-M.; Tae, H.S.; Lee, H.-Y.; Nam, K.-Y.; Han, G. Gelastatins and their hydroxamates as dual functional inhibitors for TNF-α converting enzyme and matrix metalloproteinases: Synthesis, biological evaluation, and mechanism studies. Biochem. Biophys. Res. Comm., 2006, 341(2), 627-634.
122. Chun, K.; Park, S.-K.; Kim, H.M.; Choi, Y.; Kim, M.-H.; Park, C.-H.; Joe, B.-Y.; Chun, T.G.; Choi, H.-M.; Lee, H.-Y.; Hong, S.H.; Kim, M.S.; Nam, K.-Y.; Han, G. Chromen-based TNF-α converting enzyme (TACE) inhibitors: Design, synthesis, and biological evaluation. Bioorg. Med. Chem., 2008, 16(1), 530-535.
123. Yang, J.S.; Chun, K.; Park, J.E.; Cho, M.; Seo, J.; Song, D.; Yoon, H.; Park, C.-H.; Joe, B.-Y.; Choi, J.-H.; Kim, M.-H.; Han, G. Structure based optimization of chromen-based TNF-α converting enzyme (TACE) inhibitors on S1' pocket and their quantitative structure-activity relationship (QSAR) study. Bioorg. Med. Chem., 2010, 18(24), 8618-8629.
124. Sheppeck II, J.E.; Gilmore, J.L.; Yang, A.; Chen, X.-T.; Xue, C.-B.; Roderick, J.; Liu, R.-Q.; Covington, M.B.; Decicco, C.P.; Duan, J.J.-W. Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-α converting enzyme (TACE). Bioorg. Med. Chem. Lett., 2007, 17(5), 1413-1417.
125. Sheppeck II, J.E.; Gilmore, J.L.; Tebben, A.; Xue, C.-B.; Liu, R.-Q.; Decicco, C.P.; Duan, J.J.-W. Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-α converting enzyme (TACE). Bioorg. Med. Chem. Lett., 2007, 17(10), 2769-2774.
126. Yu, W.; Guo, Z.; Orth, P.; Madison, V.; Chen, L.; Dai, C.; Feltz, R.J.; Girijavallabhan, V.M.; Kim, S.H.; Kozlowski, J.A.; Lavey, B.J.; Li, D.; Lundell, D.; Niu, X.; Piwinski, J.J.; Popovici-Muller, J.; Rizvi, R.; Rosner, K.E.; Shankar, B.B.; Shih, N.-Y.; Arshad Siddiqui, M.; Sun, J.; Tong, L.; Umland, S.; Wong, M.K.C.; Yang, D.-Y.; Zhou, G. Discovery and SAR of hydantoin TACE inhibitors. Bioorg. Med. Chem. Lett., 2010, 20(6), 1877-1880.
127. Yu, W.; Tong, L.; Kim, S.H.; Wong, M.K.C.; Chen, L.; Yang, D.-Y.; Shankar, B.B.; Lavey, B.J.; Zhou, G.; Kosinski, A.; Rizvi, R.; Li, D.; Feltz, R.J.; Piwinski, J.J.; Rosner, K.E.; Shih, N.-Y.; Arshad Siddiqui, M.; Guo, Z.; Orth, P.; Shah, H.; Sun, J.; Umland, S.; Lundell, D.J.; Niu, X.; Kozlowski, J.A. Biaryl substituted hydantoin compounds as TACE inhibitors. Bioorg. Med. Chem. Lett., 2010, 20(17), 5286-5289.
128. Girijavallabhan, V.M.; Chen, L.; Dai, C.; Feltz, R.J.; Firmansjah, L.; Li, D.; Kim, S.H.; Kozlowski, J.A.; Lavey, B.J.; Kosinski, A.; Piwinski, J.J.; Popovici-Muller, J.; Rizvi, R.; Rosner, K.E.; Shankar, B.B.; Shih, N.-Y.; Arshad Siddiqui, M.; Tong, L.; Wong, M.K.C.; Yang, D.-Y.; Yang, L.; Yu, W.; Zhou, G.; Guo, Z.; Orth, P.; Madison, V.; Bian, H.; Lundell, D.; Niu, X.; Shah, H.; Sun, J.; Umland, S. Novel TNF-α converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases. Bioorg. Med. Chem. Lett., 2010, 20(24), 7283-7287.
129. Conway, J.G.; Andrews, R.C.; Beaudet, B.; Bickett, D.M.; Boncek, V.; Brodie, T.A.; Clark, R.L.; Crumrine, R.C.; Leenitzer, M.A.; McDougald, D.L.; Han, B.; Hedeen, K.; Lin, P.; Milla, M.; Moss, M.; Pink, H.; Rabinowitz, M.H.; Tippin, T.; Scates, P.W.; Selph, J.; Stimpson, S.A.; Warner, J.; Becherer, J.D. Inhibition of tumor necrosis factor-α (TNF-α) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-α converting enzyme and matrix metalloproteinases. J. Pharmacol. Exp. Ther., 2001, 298(3), 900-908.
130. Rabinowitz, M.H.; Andrews, R.C.; David Becherer, J.; Mark Bickett, D.; Bubacz, D.G.; Conway, J.G.; Cowan, D.J.; Gaul, M.; Glennon, K.; Lambert, M.H.; Anthony Leesnitzer, M.; McDougald, D.L.; Moss, M.L.; Musso, D.L.; Rizzolio, M.C. Design of selective and soluble inhibitors of tumor necrosis factor-α converting enzyme (TACE). J. Med. Chem., 2001, 44(24), 4252-4267.
131. Skiles, J.W.; Gonnella, N.C.; Jeng, A.Y. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr. Med. Chem., 2001, 8(4), 425-474.
132. Foley, L.H.; Palermo, R.; Dunten, O.; Wang, P. Novel 5,5- disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg. Med. Chem. Lett., 2001, 11(8), 969-972.
133. Dunten, P.; Kammlott, U.; Crowther, R.; Levin, W.; Foley, L.H.; Wang, P.; Palermo, R. X-ray structure of a novel matrix metalloproteinase inhibitor complexed to stromelysin. Protein Sci., 2001, 10(5), 923-926.
134. Duan, J.J.-W.; Chen, L.; Lu, Z.; Jiang, B.; Asakawa, N.; Sheppeck II, J.E.; Liu, R.-Q.; Covington, M.B.; Pitts, W.; Kim, S.-H.; Decicco, C.P. Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-α converting enzyme (TACE). Bioorg. Med. Chem. Lett., 2007, 17(1), 266-271.
135. Rosner, K.E.; Guo, Z.; Orth, P.; Shipps Jr., G.W.; Belanger, D.B.; Chan, T.Y.; Curran, P.J.; Dai, C.; Deng, Y.; Girijavallabhan, V.M.; Hong, L.; Lavey, B.J.; Lee, J.F.; Li, D.; Liu, Z.; Popovici-Muller, J.; Ting, P.C.; Vaccaro, H.; Wang, L.; Wang, T.; Yu, W.; Zhou, G.; Niu, X.; Sun, J.; Kozlowski, J.A.; Lundell, D.J.; Madison, V.; McKittrick, B.; Piwinski, J.J.; Shih, N.-Y.; Arshad Siddiqui, M.; Strickland, C.O. The discovery of novel tartrate-based TNF-a converting enzyme (TACE) inhibitors. Bioorg. Med. Chem. Lett., 2010, 20(3), 1189-1193.
136. Annis, D.A.; Nazef, N.; Chuang, C.-C.; Scott, M.P.; Nash, H.M. A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures. J. Am. Chem. Soc., 2004, 126(47), 15495-15503.
137. Li, D.; Popovici-Muller, J.; Belanger, D.B.; Caldwell, J.; Dai, C.; David, M.; Girijavallabhan, V.M.; Lavey, B.J.; Lee, J.F.; Liu, Z.; Mazzola, R.; Rizvi, R.; Rosner, K.E.; Shankar, B.; Spitler, J.; Ting, P.C.; Vaccaro, H.; Yu, W.; Zhou, G.; Zhu, Z.; Niu, X.; Sun, J.; Guo, Z.; Orth, P.; Chen, S.; Kozlowski, J.A.; Lundell, D.J.; Madison, V.; McKittrick, B.; Piwinski, J.J.; Shih, N.-Y.; Shipps Jr., G.W.; Arshad Siddiqui, M.; Strickland, C.O. Structure and activity relationships of tartrate-based TACE inhibitors. Bioorg. Med. Chem. Lett., 2010, 20(16), 4812-4815.
138. Dai, C.; Li, D.; Popovici-Muller, J.; Zhao, L.; Girijavallabhan, V.M.; Rosner, K.E.; Lavey, B.J.; Rizvi, R.; Shankar, B.B.; Wong, M.K.C.; Guo, Z.; Orth, P.; Strickland, C.O.; Sun, J.; Niu, X.; Chen, S.; Kozlowski, J.A.; Lundell, D.J.; Piwinski, J.J.; Shih, N.-Y.; Arshad Siddiqui, M. 2-(2-Aminothiazol-4- yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors. Bioorg. Med. Chem. Lett., 2011, 21(10), 3172-3176.